Zyga Technology enrolled the 100th patient in EVoluSIon (EVSI), a prospective, 40-site, 250-patient trial investigating long-term fusion and pain reduction in patients undergoing SImmetry® Sacroiliac Joint Fusion. Enrollment had commenced just over one year ago.
At 24 months post-op, 94% of SImmetry patients had evidence of bridging bone across the SI joint, with 83% categorized as solid fusion; of those, 88% of joints were fused within the area of decortication. EVSI is designed to build on the findings of this study, which was reported earlier this month.
Zyga Technology enrolled the 100th patient in EVoluSIon (EVSI), a prospective, 40-site, 250-patient trial investigating long-term fusion and pain reduction in patients undergoing SImmetry® Sacroiliac Joint Fusion. Enrollment had commenced just over one year ago.
At 24 months post-op, 94% of SImmetry patients had evidence of bridging bone...
Zyga Technology enrolled the 100th patient in EVoluSIon (EVSI), a prospective, 40-site, 250-patient trial investigating long-term fusion and pain reduction in patients undergoing SImmetry® Sacroiliac Joint Fusion. Enrollment had commenced just over one year ago.
At 24 months post-op, 94% of SImmetry patients had evidence of bridging bone across the SI joint, with 83% categorized as solid fusion; of those, 88% of joints were fused within the area of decortication. EVSI is designed to build on the findings of this study, which was reported earlier this month.
Copy to clipboard 
